tbuckley/cabot-search huggingface dataset:
Phase II study of individualized sunitinib as first-line therapy for metastatic renal cell cancer (mRCC).
Authors: Georg A. Bjarnason, Jennifer J. Knox, Christian K. Kollmannsberger, Denis Soulieres, D. Scott Ernst, Christina M. Canil, Eric Winquist, Pawel Zalewski, Sebastien J. Hotte, Scott A. North, Daniel Yick Chin Heng, Robyn Jane Macfarlane, Peter M. Venner, Ian Tannock, Anil Kapoor, Bernhard J. Eigl, Aaron Richard Hansen, Piotr Czaykowski, Ben Boyd, Naveen S. Basappa
Journal: Journal of Clinical Oncology (2015)

4555 Background: Higher sunitinib drug exposure is associated with better response (RR), progression free (PFS) and overall survival (OS). Retrospective data show poorer PFS and OS in patients (pts) with minimum toxicity on the 28 day (d)/14 d schedule vs pts needing dose/schedule changes. We hypothesized that toxicity-driven dose/schedule changes would optimize drug exposure. Methods: In a prospective phase II study (eligibility identical to EFFECT trial, JCO 30(12):1371) with the primary endpoint of improving PFS from 8.5 (EFFECT 4/2) to 14 months (mo), pts start on 50 mg/d for 28 d with treatment (Rx) breaks reduced to 7 d. Pts with grade-2 toxicity before d 28 stay on 50 mg with the d on Rx individually reduced aiming for ≤ grade-2 toxicity. Dose is reduced to 37.5 mg in pts that do not tolerate 50 mg for at least 7 d and to 25 mg in pts that do not tolerate 37.5 mg for 7 d with individualized duration of Rx. Pts with minimum toxicity on d 28 are dose escalated to 62.5 mg and then 75 mg on a 14/7 d schedule. Pts that develop grade-2 toxicity by d 28, stay on a 28/7d schedule. Results: With accrual completed and 116 pts entered at 12 centers, 83 pts are evaluable for RR (at least two CTs 2 mo apart) with median followup of 11.6 mo (Heng favorable 25%, intermediate 63%, poor 12%). Nine pts came off study early due to toxicity (5), non-compliance (2) or global deterioration (2). Of 61 pts still on therapy, 24 are too early for RR. Of 83 evaluable pts (37 still on Rx), 18 (21.7%) were dose escalated to 62.5 mg (11) and 75 mg (7). For 39 pts (47%), who would have been dose reduced by standard criteria, a 50 mg dose was continued for 7 - 24 d, while 7 pts (8.4%) stayed on a 28d schedule. Dose was reduced to 37.5 mg in 13 pts (15.7% vs 36 - 63% in 4 trials) and to 25 mg in 6 pts (7.2 % vs 15 - 19% in 4 trials). Rx was stopped due to toxicity in 7/116 pts (6% vs 15-19% in 4 trials). Best response was complete (CR) in 4 pts, partial (PR) in 38 pts, stable (SD, median 6.4 mo on Rx) in 32 pts and progression in 9 pts (10.8% vs 24.6% in EFFECT) for a CR+PR (median 14.3 mo on Rx) rate of 50.6% (vs 32% in EFFECT) and CR+PR+SD rate of 89.2% (vs 75% in EFFECT). Conclusions: Individualized dosing is safe and feasible in a multicenter setting and associated with improved dose intensity and one of the highest RR reported for mRCC. Clinical trial information: NCT01499121.
Environmental Occurrence, Analysis, and Toxicology of Toxaphene Compounds
Authors: Henk-Jan de Geus, Harrie Besselink, Abraham Brouwer, Jarle Klungsoyr, Brendan McHugh, Eugene Nixon, Gerhard G. Rimkus, Peter G. Wester, Jacob de Boer
Journal: Environmental Health Perspectives (1999)

Toxaphene production, in quantities similar to those of polychlorinated biphenyls, has resulted in high toxaphene levels in fish from the Great Lakes and in Arctic marine mammals (up to 10 and 16 pg g-1 lipid).Because of the large variabiliity in total toxaphene data, few reliable conclusions can be drawn about trends or geographic differences in toxaphene concentrations.New developments in mass spectrometric detection using either negative chemical ionization or electron impact modes as well as in multidimensional gas chromatography recently have led researchers to suggest congener-specific approaches.Recently, several nomenclature systems have been developed for toxaphene compounds.Although all systems have specific advantages and limitations, it is suggested that an international body such as the International Union of Pure and Applied Chemistry make an attempt to obtain uniformity in the literature.Toxicologic information on individual chlorobornanes is scarce, but some reports have recently appeared.Neurotoxic effects of toxaphene exposure such as those on behavior and learning have been reported.Technical toxaphene and some individual congeners were found to be weakly estrogenic in in vitro test systems; no evidence for endocrine effects in vivo has been reported.In vitro studies show technical toxaphene and toxaphene congeners to be mutagenic.However, in vivo studies have not shown genotoxicity; therefore, a nongenotoxic mechanism is proposed.Nevertheless, toxaphene is believed to present a potential carcinogenic risk to humans.Until now, only Germany has established a legal tolerance level for toxaphene-0.1 mg kg-1 wet weight for fish.
CAR T Cells: Hitting the Pause Button
Journal: Cancer Discovery (2019)

Abstract Researchers have shown, preclinically, that the small-molecule inhibitor dasatinib can temporarily halt the action of chimeric antigen receptor (CAR) T cells without compromising therapeutic efficacy. Dasatinib's effects are reversible upon drug removal, and the hope is that this strategy could be used to mitigate cytokine release syndrome, a serious side effect of CAR T-cell therapy.
Parent and Physician
Journal: JAMA (1969)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
HAVE AGENTS AUTHORITY TO EMPLOY PHYSICIANS?
Journal: JAMA (1893)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
IV and oral acyclovir surpass topical use
Authors: C. Macek
Journal: JAMA (1982)

Acyclovir can now be used intravenously (IV) to treat herpes simplex virus (HSV) type I and II infections in immunocompromised patients with recurrent disease, as well as in otherwise healthy patients with severe primary HSV infections. And a number of clinical trials with the antiviral agent indicate that IV administration is significantly more effective than topical treatment (<i>JAMA</i>[MEDICAL NEWS] 1982;247:3040-3041, 3045). "Herpes is a systemic disease," says Lawrence Corey, MD, associate professor of laboratory medicine and microbiology at the University of Washington School of Medicine, Seattle (<i>JAMA</i>1982;248:1041-1049). He adds that for that reason it is helpful to have a systemic agent available. Corey has participated in a number of trials of acyclovir in topical, IV, and oral forms. (The last form has not yet been approved for clinical use by the Food and Drug Administration.) At the recent Interscience Conference on Antimicrobial Agents and Chemotherapy in Miami Beach,
Priority as to Cancer Theory.
Journal: JAMA (1902)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Kleine Chirurgie.
Journal: JAMA (1933)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Nω-nitro-L-arginine administration corrects peripheral vasodilation and systemic capillary hypotension and ameliorates plasma volume expansion and sodium retention in portal hypertensive rats
Authors: F Lee
Journal: Hepatology (1993)

In portal hypertensive states, peripheral vasodilation leads to sodium retention and plasma volume expansion. Nω-nitro-L-arginine, a specific biosynthesis inhibitor of the vasodilator nitric oxide, has been shown to acutely reverse peripheral vasodilation and the vascular hyporesponsiveness to endogenous and exogenous vasoconstrictors observed in portal hypertensive rats. This study investigated whether Nω-nitro-L-arginine treatment in portal hypertensive rats prevents peripheral vasodilation and therefore ameliorates plasma volume expansion and sodium retention. For 2 days before partial portal vein ligation or sham operation and then continuously for 4 days after the operation, animals received either placebo (0.9% saline) or Nω-nitro-L-arginine (˜2 μg/kg/min) intravenously through a subcutaneously implanted Alzet osmotic pump (model 2ML1; Alza, Palo Alto, CA). In portal hypertensive rats, Nω-nitro-L-arginine treatment significantly increased mean arterial pressure (placebo vs. Nω-nitro-L-arginine, 123 ± 4 vs. 150 ± 2 mm Hg, respectively; p < 0.001) and systemic vascular resistance (3.8 ± 0.2 vs. 5.6 ± 0.3 mm Hg/ml/min/100 gm body weight; p < 0.001), associated with a decrease in the cardiac index (33.5 ± 1.0 vs. 27.0 ± 1.1 ml/min/100 gm body weight; p < 0.001). Nω-nitro-L-arginine treatment also induced a decrease in plasma volume (4.6 ± 0.1 vs. 4.1 ± 0.1 ml/100 gm body weight; p < 0.001) and extracellular sodium space (39.4 ± 0.7 vs. 37.4 ± 0.4 ml/100 gm body weight; p < 0.05) without changes in serum sodium. In addition, Nω-nitro-L-arginine corrected the decreased capillary pressure observed in portal hypertensive rats. Capillary pressure negatively correlated with plasma volume but not with sodium space. In contrast, Nω-nitro-L-arginine infusions in sham-operated rats significantly elevated mean arterial pressure without modifying plasma volume and sodium space. These results demonstrate that correction of peripheral vasodilation and capillary hypotension by Nω-nitro-Larginine ameliorates plasma volume expansion and sodium retention in portal hypertensive rats. (HEPATOLOGY 1993;17:84–90.)
Joint British recommendations on prevention of coronary heart disease in clinical practice: summary
Authors: None British Cardiac Society
Journal: BMJ (2000)

For all patients with coronary heart disease (angina, myocardial infarction)or other major atherosclerotic disease, every effort should be made to achieve the lifestyle, risk factor, and therapeutic targets given in the table. The care of coronary patients should embrace all aspects of cardiac prevention and rehabilitation. #### Priorities for CHD prevention in clinical practice 1. (a) Patients with established coronary heart disease (b) Patients with other major atherosclerotic disease 2. Patients with hypertension, dyslipidaemia, diabetes mellitus, family history of premature CHD, or a combination of these risk factors, which puts them at high risk of developing CHD or other atherosclerotic disease. Patients with diabetes melitus are at particularly high risk of CHD View this table: Lifestyle, risk factor, and therapeutic targets for prevention of coronary heart disease (CHD) in patients with established CHD or other atherosclerotic disease and in healthy people at high risk of developing this disease These charts are for estimating the risk of coronary heart disease (non-fatal myocardial infarction and death from coronary heart disease) for individuals who have not developed symptoms of coronary heart disease or other major atherosclerotic disease. These charts are not appropriate for patients who have existing disease which already puts them at high risk. Such diseases are:
SURFACE TENSION OF SERUM
Authors: P. Lecomte du Noüy
Journal: The Journal of Experimental Medicine (1922)

On page 735, Vol. xxxv, No. 5, Figs. 1, 2, 3, and 4, for NaCl solution at 9 per cent read NaCl solution at 0.9 per cent. On Plate 58 of the same article, at the lower left hand corner, for NaCl 9 per cent read NaCl 0.9 per cent.
Oncogenic role of the ubiquitin ligase subunit Skp2 in human breast cancer
Authors: Sabina Signoretti, Lucia Di Marcotullio, Andrea Richardson, Sridhar Ramaswamy, Beth Isaac, Montserrat Rue, Franco Monti, Massimo Loda, Michele Pagano
Journal: Journal of Clinical Investigation (2016)

in Figures 1B, 3C, and4C.After an extensive internal review,
Oncology Research Program
Authors: Margaret Von Mehren
Journal: Journal of the National Comprehensive Cancer Network (2018)

The goal of the Highlights of the NCCN Oncology Research Program (ORP) is to provide readers with more information on the ORP, including studies currently accruing patients.For more information on specific trials, including patient selection criteria, please use the contact information listed with each study.For more information on the NCCN ORP, including a complete detailing of the clinical studies currently underway at NCCN Member Institutions, please access the NCCN ORP pages at NCCN.org/clinical_trials/ clinicians.asp.
Biological Reversion and Hippocratic Anatomy.
Journal: JAMA (1929)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Wound Sepsis and Operating-List Order
Journal: JAMA (1963)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Software
Journal: JAMA (1987)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
837. Colon-Directed Delivery of Viral Vectors Using Virus-Microbead Conjugates for Gene Therapy of Inflammatory Bowel Disease
Authors: Alan Jerusalmi, Samuel J. Farlow, Takeshi Sano
Journal: Molecular Therapy (2006)

In the course of the last few years, we have developed a novel gene transfer technology that allows for safe and efficient delivery of recombinant viral vectors to target sites for gene therapy applications. In this technology, viral particles are attached stably to the surfaces of microbeads and then delivered to target sites in the form of virus-microbead conjugates. Such conjugates can infect cells at efficiencies equivalent to or even greater than free viral vectors. In particular, the transduction of target cells, which are poorly permissive to infection by free viral vectors, can be considerably enhanced, providing the attached viral vectors with broader tropism.
Cancer Therapy
Authors: R. J. Berry
Journal: BMJ (1968)

<h3>ABSTRACT</h3> When access to diagnosis and treatment of tuberculosis is disrupted by poverty or unequal access to health services, marginalized communities not only endorse the burden of preventable deaths, but also suffer from the dramatic consequences of a disease which impacts one’s ability to access education and minimal financial incomes. Unfortunately, these pockets are often left unrecognized in the flow of data collected National tuberculosis reports, as localized hotspots are diluted in aggregated reports focusing on notified cases. Such system is therefore profoundly inadequate for identifying these marginalized groups, which urgently require adapted interventions. We computed an estimated incidence-rate map for the South-Kivu province of the Democratic Republic of Congo, a province of 6.3 million inhabitants, leveraging available data including notified incidence, level of access to health care and exposition to identifiable risk factors. These estimations were validated in a prospective multi-centric study. We could demonstrate that combining different sources of openly-available data allows to precisely identify pockets of the population which endorses the biggest part of the burden of disease. We could precisely identify areas with a predicted annual incidence of <i>&gt;</i> 1%, a value three times higher than the national estimates. While hosting only 2.5% of the total population, we estimated that these areas were responsible for 23.5% of the actual tuberculosis cases of the province. The bacteriological results obtained from systematic screenings strongly correlated with the estimated incidence (r=0.86), and much less with the incidence reported from epidemiological reports (r=0.77), highlighting the inadequacy of these reports when used alone to guide disease control programs.
Bystander Killing of Malignant Glioma by Bone Marrow–derived Tumor-Infiltrating Progenitor Cells Expressing a Suicide Gene
Authors: Hrvoje Miletic, Yvonne Fischer, Sara Litwak, Tsanan Giroglou, Yannic Waerzeggers, Alexandra Winkeler, Huongfeng Li, Uwe Himmelreich, Claudia Lange, Werner Stenzel, Martina Deckert, Harald Neumann, Andreas H Jacobs, Dorothee von Laer
Journal: Molecular Therapy (2007)